CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Hikma (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East. In all, the company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics. The most popular products from the Branded division are: Amoclan, Omnisef, Blopress, Suprax and other. Hikma share price information: Hikma shares are traded on the London Stock Exchange (LSE). The company constitutes the FTSE 250 index. Follow Capital.com to stay tuned to the Hikma Pharmaceutical share price.
Nvidia (NVDA) is down approximately 27.37% since the beginning of 2025 (as of mid-April), and up 26.48% year on year – based on its $98.78 open price on 22 April 2025.
The US Tech 100 is down approximately 5.08% year on year (as of late April 2025), and 11.21% year to date, based on its 23 April 2025 opening price of $9,201.47.
14:22, 25 April 2025
Read our reviews to find out more about us
Read the feedback from our clients, whatever their experience level.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements